Today: 22 March 2026
Subscribe
Browse Category

Stock Market 30 December 2025

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals shares fell 3.6% to $67.09 by early afternoon Tuesday, outpacing declines in biotech peers as traders positioned ahead of key January updates. The drop followed recent volatility after FDA approval of REDEMPLO, the company’s first commercial drug for familial chylomicronemia syndrome. Arrowhead plans to release interim obesity-program data and present at the J.P. Morgan Healthcare Conference in early January.
30 December 2025
··
Wells Fargo stock slips as Fed minutes loom in thin year-end trading

Wells Fargo stock slips as Fed minutes loom in thin year-end trading

Wells Fargo shares fell 0.4% to $94.15 in afternoon New York trading Tuesday, tracking declines across U.S. bank stocks ahead of Federal Reserve meeting minutes. Investors focused on rate expectations for 2026 and the bank’s upcoming earnings in mid-January. The 10-year Treasury yield rose to 4.134% as financial sector ETFs also slipped in thin, year-end trading.
30 December 2025
···
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer shares edged up 0.1% to $25.03 Tuesday after TD Cowen reiterated a Hold rating and $30 price target, citing negative trends through 2030. The company projected 2026 revenue of $59.5 billion to $62.5 billion and warned of a “bumpy” period ahead as COVID demand fades and key patents expire. Shares have dropped over 50% since early 2023. Pfizer’s next earnings report is set for February 3.
30 December 2025
··
Energy Fuels stock falls today as UUUU pulls back after uranium sales beat, new contracts

Energy Fuels stock falls today as UUUU pulls back after uranium sales beat, new contracts

Energy Fuels Inc shares fell 3.5% to $14.55 in Tuesday afternoon trading, underperforming uranium peers. The company said it exceeded 2025 uranium production guidance and completed two new long-term sales contracts with U.S. nuclear power generators. Energy Fuels expects to sell 360,000 pounds of U3O8 in Q4 for about $27 million at a weighted average price of $74.93 per pound.
30 December 2025
··
AI stocks today: Nvidia AI21 buyout talk hits tape as Meta climbs on Manus deal

AI stocks today: Nvidia AI21 buyout talk hits tape as Meta climbs on Manus deal

Nvidia traded flat after reports of advanced talks to buy Israel’s AI21 Labs for up to $3 billion. Meta gained 1.17% to $666.40 after announcing plans to acquire AI startup Manus, with the deal valued at $2 billion to $3 billion by a source. Broader tech stocks were mixed in light, year-end trading. Investors awaited Federal Reserve meeting minutes for signals on 2026 interest rates.
30 December 2025
····
Bitcoin price today steadies near $88,000 as Fed minutes loom; crypto stocks edge higher

Bitcoin price today steadies near $88,000 as Fed minutes loom; crypto stocks edge higher

Bitcoin rose 0.8% to $88,320 in New York Tuesday afternoon. U.S. spot bitcoin ETFs saw $19.3 million in net outflows Monday, led by BlackRock’s IBIT. Coinbase shares edged up 0.2%, while Strategy gained 1.4% after disclosing a $108.8 million bitcoin purchase. Fed minutes are due at 2 p.m. ET.
30 December 2025
·······
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics shares fell 3.3% to $35.61 by early afternoon Tuesday, underperforming biotech peers as investors awaited updates on its blood-pressure drug lorundrostat. The stock remains up 183% over 52 weeks but is down 25% from its November high. Mineralys plans to file for FDA approval of lorundrostat by early 2026 and expects Phase 2 results in the first quarter of that year.
30 December 2025
··
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals shares dropped 4.2% to $107.85 in early afternoon trading Tuesday as biotech stocks broadly declined. Investors are awaiting an FDA decision on expanding Imcivree’s label, now expected by March 20, 2026. Board member Camille L. Bedrosian resigned effective immediately, according to an SEC filing. Major biotech ETFs fell over 1% while the broader market was flat.
30 December 2025
··
Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

Warby Parker shares fell 3.9% to $22.11 in early afternoon trading Tuesday, underperforming the broader market amid thin year-end volumes. Nearly 3 million shares changed hands as investors awaited Federal Reserve meeting minutes. The company’s recent AI glasses partnership with Google has drawn attention, but traders remain focused on near-term fundamentals. Retail stocks were mixed, with National Vision down 1.7%.
30 December 2025
·
Dow Jones today: DJIA slips in thin year-end trade as Fed minutes loom

Dow Jones today: DJIA slips in thin year-end trade as Fed minutes loom

The Dow slipped 0.12% to 48,404.49 by early afternoon Tuesday, with financials and tech stocks weighing and communication services rising after Meta’s AI acquisition. Investors awaited Federal Reserve minutes due at 2 p.m. ET, following a recent rate cut that split policymakers. Treasury yields edged up, with the 10-year near 4.13%. The S&P 500 and Nasdaq were little changed in thin, year-end trading.
30 December 2025
·····
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept Therapeutics shares fell 8.9% to $72.72 in early afternoon trading Tuesday as investors awaited the FDA’s decision on relacorilant, due later in the day. SEC filings showed CEO Joseph Belanoff and Chief Business Officer Gary Charles Robb exercised stock options and withheld shares for taxes. About 897,000 shares changed hands. The drop outpaced declines in major biotech indexes.
30 December 2025
··
Equinox Gold stock climbs as gold rebounds — here’s what’s moving EQX today

Equinox Gold stock climbs as gold rebounds — here’s what’s moving EQX today

Equinox Gold shares rose 2.2% to around $14.30 on Tuesday as gold prices rebounded, following a sharp drop the previous day. About 2.2 million shares traded, with the stock moving between $14.18 and $14.58. Investors are watching for Federal Reserve minutes later in the day for signals on 2026 rate cuts. No major company news since Equinox announced its Brazil asset sale on Dec. 14.
30 December 2025
··
Target stock slips today as activist pressure stays in focus — what investors are watching next

Target stock slips today as activist pressure stays in focus — what investors are watching next

Target shares fell 0.7% to $97.38 in midday trading Tuesday, underperforming a weaker retail sector. The move follows reports that hedge fund Toms Capital Investment Management has taken a significant, undisclosed stake as Target prepares for a CEO transition in February. Investors await filings that could reveal TCIM’s intentions. Target shares are down more than 28% in 2025.
30 December 2025
·
1 … 718 719 720 721 722 … 1,358

Stock Market Today

  • Strategy's New Bitcoin Funding Tool Called 'iPhone Moment' Amid Warning Over Hidden Risks
    March 22, 2026, 1:11 PM EDT. Strategy's launch of Perpetual Stretch Preferred Stock (STRC) marks a significant step in corporate bitcoin funding, dubbed an "iPhone moment" by the company. STRC maintains a $100 share price by adjusting dividends, enabling billion-dollar capital raises for bitcoin purchases, with the firm acquiring over $3.5 billion in bitcoin so far. NYDIG notes the product requires unique analysis beyond traditional equity or credit metrics. While STRC offers high yields around 11.5% and has institutional appeal, BitMEX Research warns of risks exceeding those of short-duration U.S. Treasuries. Despite Strategy's substantial bitcoin reserves and cash cushioning dividend payments, analysts caution that the primary risks lie beyond simple dividend coverage. Investors should weigh the novel structure's strengths against potential hidden financial vulnerabilities.
Go toTop